Comprehensive Guide to Metabotropic Receptors and GPCR Signaling

Foundations: Ionotropic vs. Metabotropic Receptor Architecture

• Fundamental Classification of Neurotransmitter Receptors:
  • Neurotransmitter receptors in the nervous system are partitioned into two broad functional and structural classes: ionotropic receptors (ligand-gated ion channels) and metabotropic receptors (G-protein coupled receptors, or GPCRs).
  • Ionotropic Receptors: Integral membrane channel assemblies that open a central ion-conducting pore directly upon ligand binding, generating rapid postsynaptic potentials lasting milliseconds.
  • Metabotropic Receptors: Monomeric or dimeric seven-transmembrane proteins that signal through heterotrimeric G-proteins to initiate second messenger cascades or indirectly gate ion channels, operating on slower timeframes ranging from hundreds of milliseconds to minutes and hours.

• Structural Principles of Major Ionotropic Receptor Superfamilies:
  • Cys-Loop Receptors (Pentamers):
  • Stoichiometry: Five symmetrical subunits surrounding a central aqueous pore.
  • Transmembrane topology: Each individual subunit possesses $4$ transmembrane domains (TMDs), designated M1 through M4, with large extracellular N- and C-termini.
  • Ion selectivity:
    • Nicotinic Acetylcholine Receptors (nAChRs): Cation-selective, passing $\text{Na}^+$ and $\text{K}^+$.
    • $GABA_A$ Receptors: Anion-selective, permeable to $\text{Cl}^-$.
    • Glycine Receptors: Anion-selective, permeable to $\text{Cl}^-$.

• Ionotropic Glutamate Receptors (iGluRs - Tetramers):
  • Stoichiometry: Heterotetrameric or homotetrameric assemblies ($4$ subunits).
  • Transmembrane topology: Each subunit consists of $3$ true transmembrane helices (M1, M3, M4) and a re-entrant pore loop (M2) dipping into the cytoplasmic side of the membrane rather than spanning it completely.
  • Structural domains:
    • Amino-terminal domain (ATD): Involved in receptor assembly and allosteric modulation.
    • Ligand-binding domain (LBD): Forms a "clamshell" structure that binds glutamate.
    • Transmembrane domain (TMD): Forms the ion-conducting pore.
    • Carboxyl-terminal domain (CTD): Intracellular region participating in intracellular trafficking and protein-protein interactions.
  • Subfamilies and functional properties:
    • GluA (AMPA receptors) and GluK (Kainate receptors): Conduct $\text{Na}^+$ and $\text{K}^+$; permeability to $\text{Ca}^{2+}$ is regulated by post-transcriptional RNA editing at the Q/R pore loop site.
    • GluN (NMDA receptors): Permeable to $\text{Na}^+$, $\text{K}^+$, and highly permeable to $\text{Ca}^{2+}$; susceptible to a voltage-dependent pore block by extracellular magnesium ($\text{Mg}^{2+}$) at resting membrane potentials.

• Determinants of Synaptic Polarity (EPSP vs. IPSP):
  • The functional outcome of ionotropic receptor activation—whether an Excitatory Postsynaptic Potential (EPSP) or an Inhibitory Postsynaptic Potential (IPSP) is generated—depends strictly on the relationship between the resting membrane potential ($V_{\text{rest}}$), the action potential threshold, and the reversal potential ($E_{\text{rev}}$) of the conducting ion channel relative to the threshold.
  • Excitatory Synaptic Transmission (Glutamate, ACh):
  • Opening non-selective cation channels conducts both $\text{Na}^+$ ($E_{\text{Na}} \approx +50\,\text{mV}$) and $\text{K}^+$ ($E_{\text{K}} \approx -110\,\text{mV}$).
  • The net reversal potential ($E_{\text{rev}}$) stabilizes near $0\,\text{mV}$.
  • Because $E_{\text{rev}} = 0\,\text{mV}$ lies significantly more depolarized than both the resting membrane potential ($V_{\text{rest}} \approx -60\,\text{mV}$) and the action potential threshold ($\approx -40\,\text{mV}$), activation drives net inward positive current, causing membrane depolarization (EPSP) that promotes action potential generation.
  • Inhibitory Synaptic Transmission (GABA, Glycine):
  • Opening selective anion channels conducts $\text{Cl}^-$ with an equilibrium reversal potential around $E_{\text{rev}} \approx -70\,\text{mV}$.
  • If the membrane potential is elevated above $-70\,\text{mV}$, activation drives $\text{Cl}^-$ influx, hyperpolarizing the membrane below $V_{\text{rest}}$ (IPSP).
  • If the membrane is clamped or resting near $E_{\text{Cl}}$, opening chloride channels locks the membrane potential below the threshold for voltage-gated sodium channel activation (shunting inhibition).

• Comparative Distribution of Neurotransmitter Receptor Classes:
  • Ligands utilizing ionotropic channels: Acetylcholine (nAChRs), GABA ($\text{GABA}_A$), Glutamate (AMPA, Kainate, NMDA), Glycine (Glycine receptor), Serotonin ($5\text{-}\text{HT}_3$ only), and ATP ($\text{P2X}$ receptors).
  • Ligands utilizing metabotropic receptors: Acetylcholine (muscarinic mACh receptors $M_1\text{–}M_5$), GABA ($\text{GABA}_B$ receptors), Glutamate (mGluRs $mGlu_1\text{–}mGlu_8$), Biogenic Amines (Dopamine, Norepinephrine, Epinephrine, Histamine, Serotonin [$5\text{-}\text{HT}_{1,2,4,5,6,7}$]), Purines (Adenosine receptors, $\text{P2Y}$ receptors), and all peptide neurotransmitters without exception.

Molecular Architecture and Signaling Mechanics of GPCRs

• Core Structural Organization of GPCRs:
  • Constitutes a massive superfamily comprising over $1000$ unique receptor genes.
  • Conserved topology across all GPCRs consists of a single polypeptide chain folded into $7$ hydrophobic transmembrane $\alpha$-helices (H1 through H7).
  • Extracellular Domain: Extracellular amino terminus ($\text{NH}_3^+$ or E1) along with three extracellular peptide loops (E2, E3, E4) forming ligand-binding pockets or recognition regions.
  • Intracellular Domain: Intracellular carboxyl terminus ($\text{COO}^-$ or C4) along with three cytoplasmic loops (C1, C2, C3).
  • G-Protein Interaction Sites: Specifically localized to intracellular loops C2 and C3 as well as the juxtamembrane region of the carboxyl-terminal tail; these regions dictate coupling specificity to downstream heterotrimeric G-protein complexes.

• The Heterotrimeric G-Protein Activation Cycle:
  • Components:
  • The signaling unit operates via a tripartite cascade: $\text{GPCR} \rightarrow \text{G-Protein} \rightarrow \text{Effector Protein}$.
  • Heterotrimeric G-proteins consist of three distinct polypeptide subunits: $\alpha$, $\beta$, and $\gamma$.
  • Quiescent (Basal) State:
  • The $\alpha$ subunit holds guanosine diphosphate (GDP) in its nucleotide-binding pocket and remains tightly associated with the stable $\beta\gamma$ heterodimer.
  • Ligand Activation and Dissociation:
  1. Agonist binding to the extracellular/transmembrane core of the GPCR induces a conformational reorganization that shifts transmembrane helices H5 and H6.
  2. This structural transition exposes the cytoplasmic docking groove, recruiting the heterotrimeric G-protein complex.
  3. The intracellular receptor domain acts as a guanine nucleotide exchange factor (GEF), facilitating the release of GDP from the $\alpha$ subunit.
  4. Ambient guanosine triphosphate (GTP) binds to the vacant nucleotide site of the $\alpha$ subunit.
  5. GTP binding causes conformational rearrangements within the switch regions of the $\alpha$ subunit, driving physical dissociation of the $\alpha\text{-GTP}$ monomer from both the activated receptor and the $\beta\gamma$ heterodimer.
  6. Both liberated $\alpha\text{-GTP}$ and free $\beta\gamma$ complexes diffuse laterally along the inner leaflet of the plasma membrane to interact directly with dedicated enzymatic effectors or ion channels.
  • Hydrolysis and Cycle Termination:
  • The $\alpha$ subunit possesses intrinsic GTPase activity, hydrolyzing bound GTP to GDP and inorganic phosphate ($\text{P}_i$).
  • GTPase-Activating Proteins (GAPs) accelerate this intrinsic hydrolysis rate by several orders of magnitude, shortening the active signaling duration.
  • Once GTP is hydrolyzed to GDP, the $\alpha\text{-GDP}$ monomer loses affinity for its downstream effector and rapidly re-associates with the $\beta\gamma$ heterodimer, regenerating the basal inactive heterotrimer.

• Canonical GPCR Effector Signaling Pathways:

• The $G_{\alpha s}$ Pathway (Stimulatory):
  • Classical activator: Norepinephrine acting at $\beta$-adrenergic receptors.
  • Coupling: Receptors activate $G_{\alpha s}$.
  • Primary effector: Adenylyl cyclase.
  • Second messenger: Stimulates conversion of ATP to cyclic adenosine monophosphate (cAMP).
  • Downstream effector: Elevation of cAMP binds the regulatory subunits of Protein Kinase A (PKA), releasing active catalytic subunits.
  • Cellular response: Widespread increase in target protein phosphorylation (e.g., phosphorylating voltage-gated ion channels, metabolic enzymes, and transcription factors like CREB).
• The $G_{\alpha q}$ Pathway:
  • Classical activator: Glutamate acting at Group I metabotropic glutamate receptors ($\text{mGluR}_1, \text{mGluR}_5$).
  • Coupling: Receptors activate $G_{\alpha q}$.
  • Primary effector: Phospholipase C (PLC).
  • Second messengers: Hydrolyzes phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) into two second messengers:
    • Diacylglycerol (DAG): Hydrophobic messenger remaining embedded in the inner leaflet of the plasma membrane.
    • Inositol 1,4,5-trisphosphate ($\text{IP}_3$): Soluble hydrophilic messenger diffusing freely into the cytoplasm.
  • Downstream effectors:
    • DAG coordinates with membrane phospholipids to activate Protein Kinase C (PKC).
    • $\text{IP}_3$ docks at $\text{IP}_3$-gated calcium release channels on the smooth endoplasmic reticulum, liberating sequestered $\text{Ca}^{2+}$ into the cytosol.
  • Cellular response: Synergistic increase in protein phosphorylation (via PKC) and broad activation of calcium-binding proteins (including calmodulin and CaMKII).
• The $G_{\alpha i}$ Pathway (Inhibitory):
  • Classical activator: Dopamine acting at $D_2$ dopamine receptors.
  • Coupling: Receptors activate $G_{\alpha i}$.
  • Primary effector: Adenylyl cyclase.
  • Second messenger: Direct enzymatic inhibition of adenylyl cyclase, depressing basal cAMP production.
  • Downstream effector: Reduced cAMP levels induce dissociation failure of PKA, leading to suppressed PKA kinase activity.
  • Cellular response: Net reduction in protein phosphorylation across downstream targets, opposing the actions of $G_{\alpha s}$.

Muscarinic Acetylcholine Receptors (mAChRs)

• Receptor Classification and Distribution:
  • Muscarinic receptors are seven-transmembrane GPCRs named based on their selective activation by the fungal alkaloid muscarine, derived from the toxic mushroom Amanita muscaria.
  • Mediate the vast majority of cholinergic actions in the central nervous system (CNS), contrasting with nicotinic receptors which predominate at neuromuscular junctions.
  • Drive parasympathetic and sympathetic autonomic cholinergic responses in peripheral target organs (heart, gastrointestinal tract, smooth muscle, and exocrine glands).
  • Divided into $5$ distinct receptor subtypes ($M_1, M_2, M_3, M_4, M_5$) grouped into two functional classes:
  • $M_1, M_3, M_5$ Subtypes:
    • Coupling: Signal preferentially through $G_{\alpha q}$.
    • Cellular mechanics: Activate Phospholipase C, increasing $\text{IP}_3$, DAG, and cytosolic $\text{Ca}^{2+}$.
    • Distribution & function: Widely expressed across both the CNS and peripheral nervous system (PNS); prominently drive smooth muscle contraction in organs and stimulate secretory output in exocrine and endocrine glands.
  • $M_2, M_4$ Subtypes:
    • Coupling: Signal preferentially through $G_{\alpha i}$.
    • Cellular mechanics: Inhibit adenylyl cyclase, reduce cAMP accumulation, and release $\beta\gamma$ subunits that activate inward-rectifying potassium channels ($\text{GIRK}$).
    • Distribution & function: Co-distributed in CNS circuits and cardiac tissue; prominent in the sinoatrial node where activation slows heart frequency (bradycardia).

Metabotropic Glutamate Receptors (mGluRs)

• Structural Features of mGluRs:
  • Belong to Class C GPCRs and operate as obligate structural homodimers linked by extracellular disulfide bridges.
  • Unique domain architecture:
  • Venus Flytrap Domain (VFD): Large bilobed extracellular amino-terminal region that encases the orthosteric glutamate binding pocket. Ligand binding stabilizes a closed, active conformation resembling a Venus flytrap.
  • Cysteine-Rich Domain (CRD): Rigid disulfide-linked stalk connecting the VFD directly to the transmembrane domain, transducing ligand-induced clamshell closure into structural shifts across the membrane.
  • Transmembrane Domain (TMD): Classical 7-TMD core responsible for engaging heterotrimeric G-proteins.

• Isoform Classification and Signaling Groups:

  • At least $8$ different isoforms ($\text{mGluR}_1$ through $\text{mGluR}_8$) partitioned into three functional classes:
  • Group I ($\text{mGluR}_1, \text{mGluR}_5$):
    • Coupling: Coupled to $G_{\alpha q}$.
    • Downstream signaling: Activates PLC, elevates intracellular $\text{Ca}^{2+}$, and stimulates PKC.
    • Physiological role: Primarily localized postsynaptically; critical for mediating long-term depression (LTD) at CA1 hippocampal synapses and enhancing excitability.
  • Group II ($\text{mGluR}_2, \text{mGluR}_3$ [and $\text{mGluR}_4$ in some structural contexts]):
    • Coupling: Coupled to $G_{\alpha i}$.
    • Downstream signaling: Suppresses adenylyl cyclase, lowering intracellular cAMP.
    • Physiological role: Prominently located on presynaptic terminals acting as autoreceptors that inhibit neurotransmitter exocytosis.
  • Group III ($\text{mGluR}_4, \text{mGluR}_6, \text{mGluR}_7, \text{mGluR}_8$):
    • Coupling: Coupled to $G_{\alpha i}$.
    • Downstream signaling: Suppresses adenylyl cyclase activity.
    • Physiological role: Typically localized presynaptically to mediate feedback inhibition; $\text{mGluR}_6$ is uniquely specialized in retinal ON-bipolar cell dendritic cascades.
  • General Roles in Neurotransmission:
  • Generate slow, modulatory postsynaptic responses.
  • Exert both excitatory and inhibitory actions depending on target coupling.
  • Frequently mediate physiological inhibition of voltage-gated $\text{Na}^+$ and $\text{Ca}^{2+}$ inward currents.

• Comparison: Ionotropic vs. Metabotropic Glutamate Receptors:

  • Structural Organization:
  • iGluRs: Tetramers ($4$ subunits) forming an ion channel directly; bind allosteric modulators on the ATD/LBD and pore blockers within the channel lumen.
  • mGluRs: Homodimers ($2$ subunits) possessing extracellular Venus flytrap domains (VFD), cysteine-rich linkers (CRD), and 7-TMD bundles; bind orthosteric agonists inside the clamshell and allosteric modulators within the transmembrane bundle.
  • Temporal Dynamics and Plasticity:
  • iGluRs mediate fast transmission and initiate short-term plasticity (AMPA/Kainate activation at $10^{-4}\text{–}10^{-3}\,\text{s}$, followed by desensitization and NMDA receptor gating at $10^{-2}\text{–}1\,\text{s}$, recovering across $1\,\text{s}$).
  • mGluRs control slower downstream signaling and participate in long-term plasticity (G-protein activation and second-messenger channel modulation initiate at $10^{-1}\text{–}1\,\text{s}$; arrestin and kinase signaling operate from $1\text{–}10^2\,\text{s}$; receptor trafficking, protein translation, and gene transcription span $10^2\text{–}10^4\,\text{s}$).

Metabotropic $\text{GABA}_B$ Receptors

• Obligate Heterodimerization:
  • Active $\text{GABA}_B$ receptors function exclusively as non-covalent heterodimers consisting of two distinct seven-transmembrane subunits: $\text{GABA}_{B1}$ and $\text{GABA}_{B2}$.
  • $\text{GABA}_{B1}$ Subunit: Contains the extracellular Venus flytrap domain responsible for binding the endogenous ligand GABA; cannot signal to G-proteins efficiently on its own.
  • $\text{GABA}_{B2}$ Subunit: Contains the transmembrane bundle and cytoplasmic loops required to couple to and activate downstream heterotrimeric G-proteins; cannot bind GABA with high affinity on its own.

• Signaling Mechanisms and Physiological Actions:
  • Distributed extensively throughout the CNS and autonomic control centers, frequently co-localizing postsynaptically with ionotropic $\text{GABA}_A$ receptors.
  • Coupled to the pertussis toxin-sensitive $G_{\alpha i/o}$ subclass.
  • Ion Channel Modulation via $\beta\gamma$ Subunits:
  • Direct binding of released $\beta\gamma$ dimers activates G-protein-coupled inwardly rectifying potassium channels ($\text{GIRK}$), driving $\text{K}^+$ efflux that produces slow, sustained inhibitory postsynaptic hyperpolarization.
  • Simultaneously, free $\beta\gamma$ subunits inhibit presynaptic voltage-gated calcium channels ($\text{Ca}_V2.1, \text{Ca}_V2.2$), suppressing inward $\text{Ca}^{2+}$ transients and terminating neurotransmitter exocytosis.
  • Adenylyl Cyclase Inhibition via $G_{\alpha i/o}$:
  • The liberated $G_{\alpha i/o}$ subunit binds adenylyl cyclase directly, depressing cyclic AMP synthesis and downregulating protein kinase A activity.
  • Cytoskeletal Scaffolding and Protein Interactions:
  • The intracellular C-terminal tail of $\text{GABA}_{B1}$ and $\text{GABA}_{B2}$ forms a coiled-coil interaction domain that recruits scaffolding proteins, transcription factors, cell adhesion molecules, and trafficking regulators.
  • Complexes link via $\beta$-filamin directly to the submembranous actin microfilament cytoskeleton, anchoring the receptor complex at synaptic junctions.

Biogenic Amine Receptors

• Overview of Biogenic Amines:
  • Act throughout the central and peripheral nervous systems to regulate complex functions: homeostatic state regulation, sleep-wake architecture, motor coordination, attention, cognition, and mood.
  • Centrally implicated in major psychiatric and neurologic disorders (schizophrenia, depression, addiction, and Parkinson's disease).
  • Divided chemically into three major structural classes:
  • Catecholamines: Dopamine, Norepinephrine (noradrenaline), Epinephrine (adrenaline).
  • Indoleamine: Serotonin ($5\text{-}\text{hydroxytryptamine}$ or $5\text{-}\text{HT}$).
  • Imidazoleamine: Histamine.

• Catecholamine Biosynthetic Pathway:
  • All catecholamines share a common enzymatic synthesis pathway initiating from the precursor amino acid L-tyrosine:
  1. Tyrosine to DOPA: L-tyrosine is hydroxylated by the rate-limiting enzyme Tyrosine Hydroxylase (requiring molecular oxygen, $O_2$), adding a hydroxyl group to synthesize Dihydroxyphenylalanine (DOPA).
  2. DOPA to Dopamine: DOPA undergoes decarboxylation by DOPA Decarboxylase, releasing carbon dioxide ($CO_2$) to form Dopamine.
  3. Dopamine to Norepinephrine: In noradrenergic neurons, Dopamine is packaged into vesicles and hydroxylated at the $\beta$-carbon by Dopamine-$\beta$-hydroxylase (requiring $O_2$) to yield Norepinephrine.
  4. Norepinephrine to Epinephrine: In adrenergic cells and the adrenal medulla, Norepinephrine is methylated at its terminal amino group by Phenylethanolamine $N$-methyltransferase (using an active methyl donor, $R\text{-}CH_3$) to produce Epinephrine.

• Dopamine Receptors:
  • All dopamine receptors are metabotropic GPCRs; no ionotropic dopamine receptors exist.
  • Concentrated heavily within the striatum (caudate and putamen), where they regulate motor execution, as well as the nucleus accumbens and prefrontal cortex, where they govern motivation, reinforcement, and reward learning.
  • Divided into $5$ distinct subtypes ($D_1$ through $D_5$) organized into two functional families:
  • $D_1$-like Family ($D_1$ and $D_5$): Couple to $G_{\alpha s}$ to stimulate adenylyl cyclase, elevating cAMP and activating PKA.
  • $D_2$-like Family ($D_2, D_3, D_4$): Couple to $G_{\alpha i}$ to inhibit adenylyl cyclase, decreasing cAMP and suppressing PKA activity.

• Adrenergic Receptors (Norepinephrine and Epinephrine):
  • Both endogenous catecholamines (norepinephrine and epinephrine) bind promiscuously across $\alpha$- and $\beta$-adrenergic receptor families.
  • Divided into three major families ($\alpha_1$, $\alpha_2$, and $\beta$), which further subdivide into nine distinct subtypes:
  • $\alpha_1$ Adrenergic Family ($\alpha_{1A}, \alpha_{1B}, \alpha_{1D}$):
    • Coupling: Coupled to $G_{\alpha q}$.
    • Cellular mechanism: Stimulates PLC, generating $\text{IP}_3$ and DAG to elevate intracellular $\text{Ca}^{2+}$.
    • Distribution: Expressed in sympathetic postganglionic target tissues, vascular smooth muscle, cardiac tissue, and the hippocampus.
  • $\alpha_2$ Adrenergic Family ($\alpha_{2A}, \alpha_{2B}, \alpha_{2C}$):
    • Coupling: Coupled to $G_{\alpha i}$.
    • Cellular mechanism: Inhibits adenylyl cyclase, lowers cAMP, and suppresses presynaptic voltage-gated calcium entry.
    • Distribution: Abundant on sympathetic postganglionic terminals and central noradrenergic terminals (acting as inhibitory autoreceptors), as well as within cardiac tissue.
  • $\beta$ Adrenergic Family ($\beta_1, \beta_2, \beta_3$):
    • Coupling: Coupled to $G_{\alpha s}$.
    • Cellular mechanism: Stimulates adenylyl cyclase, elevating intracellular cAMP and activating PKA.
    • Distribution: Prominent in cardiac tissue ($\beta_1$, increasing contractility and heart rate), sympathetic neurons, vascular and bronchial smooth muscle ($\beta_2$), adipose tissue ($\beta_3$), and central nuclei such as the caudate nucleus.

• Histamine Receptors:

  • Histaminergic cell bodies are localized exclusively within the tuberomammillary nucleus of the posterior hypothalamus, projecting throughout the neuroaxis.
  • Mediate physiological arousal, vigilance, attention, energy balance, and vestibular reflexes.
  • All four subtypes ($H_1, H_2, H_3, H_4$) are metabotropic GPCRs:
  • $H_1$ Receptors: Coupled to $G_{\alpha q}$; central antagonism drives sedation, while activation in vestibular circuits is linked to motion sickness.
  • $H_2$ Receptors: Coupled to $G_{\alpha s}$; potent stimulators of gastric acid secretion from parietal cells in the stomach mucosa (major pharmacological target for acid suppression).
  • $H_3$ and $H_4$ Receptors: Coupled to $G_{\alpha i/o}$; $H_3$ operates primarily as an inhibitory autoreceptor/heteroreceptor in the brain, while $H_4$ modulates immune and inflammatory chemotaxis.

• Serotonin ($5\text{-}\text{HT}$) Receptors:

  • Serotonergic neurons originate primarily within the brainstem raphe nuclei, sending projections across the entire neuraxis to modulate mood, appetite, sleep-wake cycles, circadian rhythmicity, and pain processing.
  • Highly diverse receptor portfolio partitioned across $7$ major subfamilies ($5\text{-}\text{HT}_1$ through $5\text{-}\text{HT}_7$):
  • $5\text{-}\text{HT}_1$ Family ($5\text{-}\text{HT}_{1A}, 5\text{-}\text{HT}_{1B}, 5\text{-}\text{HT}_{1D}, 5\text{-}\text{HT}_{1E}, 5\text{-}\text{HT}_{1F}$): Coupled to $G_{\alpha i}$.
  • $5\text{-}\text{HT}_2$ Family ($5\text{-}\text{HT}_{2A}, 5\text{-}\text{HT}_{2B}, 5\text{-}\text{HT}_{2C}$): Coupled to $G_{\alpha q}$.
  • $5\text{-}\text{HT}_3$ Receptor: The ONLY ionotropic serotonin receptor. Operates as a non-selective cation channel ($\text{Na}^+, \text{K}^+$) belonging to the cys-loop pentameric superfamily.
  • $5\text{-}\text{HT}_4, 5\text{-}\text{HT}_6, 5\text{-}\text{HT}_7$ Receptors: Coupled to $G_{\alpha s}$.
  • $5\text{-}\text{HT}_5$ Family ($5\text{-}\text{HT}_{5A}$): Coupled to $G_{\alpha i}$.
  • High-affinity targets for psychotropic agents: Serotonin GPCRs, particularly $5\text{-}\text{HT}_{2A}$, serve as primary binding targets for hallucinogens such as lysergic acid diethylamide (LSD).

Purinergic Receptors

• Cotransmission and Metabolic Generation:

  • Adenosine triphosphate (ATP) is stoichiometric with classical transmitters; virtually all synaptic vesicles co-package ATP.
  • Upon exocytosis, ATP functions as an excitatory cotransmitter in both the central nervous system, autonomic ganglia, and peripheral motor synapses in the spinal cord.
  • In the synaptic cleft, extracellular nucleotidases rapidly catabolize released ATP: $\text{ATP} \rightarrow \text{ADP} \rightarrow \text{AMP} \rightarrow \text{Adenosine}$.
  • Key Distinction: While adenosine activates specialized cell-surface purinergic receptors, it is not packaged into vesicles and is therefore not categorized as a classical neurotransmitter.

• Purinergic Receptor Families:

  • $P2X$ Family (Ionotropic):
  • Non-selective cation channels ($\text{Na}^+, \text{K}^+, \text{Ca}^{2+}$) assembled as homotrimers or heterotrimers.
  • Directly gated by extracellular ATP.
  • $P2Y$ Family (Metabotropic):
  • Seven-transmembrane GPCRs gated by extracellular nucleotides ($\text{ATP}$, $\text{ADP}$, $\text{UTP}$, $\text{UDP}$, and $\text{UDP-glucose}$).
  • Comprises $8$ distinct human subtypes: $\text{P2Y}_1, \text{P2Y}_2, \text{P2Y}_4, \text{P2Y}_6, \text{P2Y}_{11}, \text{P2Y}_{12}, \text{P2Y}_{13}, \text{P2Y}_{14}$.
  • Signal via $G_{\alpha q}$ ($\text{P2Y}_1, \text{P2Y}_2, \text{P2Y}_4, \text{P2Y}_6$) or $G_{\alpha i}$ ($\text{P2Y}_{12}, \text{P2Y}_{13}, \text{P2Y}_{14}$).
  • Adenosine Receptors (Metabotropic):
  • G-protein coupled receptors selective for extracellular adenosine.
  • Comprises $4$ subtypes:
    • $A_1$ and $A_3$: Coupled to $G_{\alpha i}$, mediating inhibition of adenylyl cyclase.
    • $A_{2A}$ and $A_{2B}$: Coupled to $G_{\alpha s}$, stimulating adenylyl cyclase.
  • Classical targets of methylxanthine stimulants (e.g., caffeine, theophylline), which act as competitive antagonists at $A_1$ and $A_{2A}$ receptors.

Neuropeptides and Neuropeptide Receptors

• General Properties of Peptidergic Transmission:

  • All neuropeptide receptors are metabotropic GPCRs. No ionotropic neuropeptide receptors exist.
  • Neuropeptides display nanomolar to picomolar affinities ($10^{-9}\text{–}10^{-12}\,\text{M}$) for their receptors, allowing them to signal effectively at extremely low concentrations.
  • Peptides undergo volumetric diffusion, acting over extensive distances away from their nonsynaptic release sites (volume transmission), unlike classical small-molecule transmitters that operate locally within the synaptic cleft.

• Structural Inventory and Primary Amino Acid Sequences:

• Brain-Gut Peptides:

  • Substance P ($11$ amino acids): $\text{Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met}$
  • Cholecystokinin octapeptide (CCK-8) ($8$ amino acids): $\text{Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe}$
  • Vasoactive intestinal peptide (VIP) ($28$ amino acids): $\text{His-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn}$

• Opioid Peptides:

  • Leucine enkephalin ($5$ amino acids): $\text{Tyr-Gly-Gly-Phe-Leu}$
  • $\alpha$-Endorphin ($16$ amino acids): $\text{Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr}$
  • Dynorphin A ($17$ amino acids): $\text{Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln}$

• Pituitary Peptides:

  • Vasopressin ($9$ amino acids): $\text{Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg/Lys-Gly}$
  • Oxytocin ($9$ amino acids): $\text{Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly}$
  • Adrenocorticotropic hormone (ACTH) ($24$ amino acids shown): $\text{Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro}$

• Hypothalamic-Releasing Peptides:

  • Thyrotropin releasing hormone (TRH) ($3$ amino acids): $\text{Glu-His-Pro}$
  • Luteinizing hormone-releasing hormone (LHRH) ($10$ amino acids): $\text{Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly}$
  • Somatostatin 14 ($14$ amino acids): $\text{Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys}$

• Miscellaneous Peptides:

  • Angiotensin II ($8$ amino acids): $\text{Asp-Arg-Val-Tyr-Ile-His-Pro-Phe}$

  • Neuropeptide Y ($36$ amino acids): $\text{Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr}$

  • Neurotensin ($13$ amino acids): $\text{Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Ile-Leu}$

  • Opioid Receptors:

• Three major functional classes:

  • $\mu$ (mu) Opioid Receptor (MOR): Most broadly distributed opioid receptor subtype across the central and peripheral nervous systems; primary molecular mediator of analgesia, respiratory depression, euphoria, and physical dependence.
  • $\kappa$ (kappa) Opioid Receptor (KOR): Gated selectively by dynorphin peptides; produces analgesia, dysphoria, and diuresis.
  • $\delta$ (delta) Opioid Receptor (DOR): Preferentially binds enkephalins; modulates thermal/mechanical analgesia and affective behaviors.

• Coupling: Signal primarily through $G_{\alpha i/o}$ (and in specific contexts $G_{\alpha q}$).

• Mechanism of Analgesia:

  • Effector coupling closes presynaptic voltage-dependent $\text{Ca}^{2+}$ channels via $G_{\beta\gamma}$ dimers, preventing primary nociceptive afferents from releasing glutamate and substance P.
  • Concurrently opens postsynaptic inwardly rectifying $\text{K}^+$ channels ($\text{GIRK}$), hyperpolarizing second-order projection neurons in the dorsal horn of the spinal cord.

• Endogenous ligands: Enkephalins, endorphins, and dynorphins.

• Exogenous agonists: Morphine and other natural opiates derived from the latex exudate of the opium poppy (Papaver somniferum).

• Cannabinoid Receptors:
  • Subtypes:
  • $CB_1$ Receptors: Enriched at very high densities throughout the central nervous system (basal ganglia, substantia nigra, cerebellum, hippocampus, and cerebral cortex), where they localize presynaptically to mediate retrograde inhibition of transmitter release.
  • $CB_2$ Receptors: Expressed predominantly in peripheral lymphoid organs and microglial cells, modulating immune responses and neuroinflammation.
  • Coupling: Couple to $G_{\alpha i}$, suppressing adenylyl cyclase and inhibiting presynaptic calcium entry.
  • Endogenous Ligands (Endocannabinoids): Lipid-derived messengers synthesized on demand from membrane lipids, primarily anandamide (arachidonoylethanolamide) and 2-arachidonoylglycerol (2-AG).
  • Exogenous Agonists: $\Delta^9$-tetrahydrocannabinol ($\Delta^9$-THC) derived from Cannabis sativa.

Take-Home Principles of Metabotropic Signaling

• Superfamily Identity: All metabotropic neurotransmitter receptors belong to the G-Protein Coupled Receptor (GPCR) superfamily, characterized by a seven-transmembrane architecture.
• Dual Modes of Synaptic Transmission:
  1. Mediate slow, direct synaptic transmission.
  2. Extensively modulate and recalibrate fast synaptic transmission mediated by ionotropic channels.
• Core Structure: A seven-transmembrane polypeptide whose intracellular loops engage a soluble heterotrimeric G-protein ($\alpha\beta\gamma$) to transduce signals.
• Structural Exceptions: While most GPCRs function as monomers, metabotropic Glutamate (mGluR) and metabotropic GABA ($\text{GABA}_B$) receptors function as structural dimers equipped with large extracellular clamshell-like "Venus flytrap" domains.
• Functional Diversity: Enormous functional and spatial diversity is achieved by combinatorial assembly of divergent receptor subunits with differing ligand affinities and downstream G-protein coupling profiles.

Questions & Discussion

• Question: Metabotropic receptors bind their signaling partner at the extracellular domains.

  • Response: True. The endogenous neurotransmitter or exogenous agonist binds directly to extracellular loops or the extracellular amino-terminal/Venus flytrap domain of the GPCR, which then induces conformational changes that transmit across the membrane.

• Question: Metabotropic receptors lead to changes in postsynaptic potential.

  • Response: True. Although metabotropic receptors lack an intrinsic ion channel pore, downstream signaling pathways (particularly through free $G_{\beta\gamma}$ subunits or protein kinase phosphorylation) open or close nearby ion channels (e.g., opening $\text{GIRK}$ potassium channels or closing calcium channels), directly altering the postsynaptic membrane potential.

• Question: Only ionotropic receptors can be inhibitory, metabotropic receptors are always excitatory.

  • Response: False. Metabotropic receptors can be potently inhibitory. Receptors coupling to $G_{\alpha i/o}$ (such as $\text{GABA}_B$, $D_2$-like dopamine receptors, $\alpha_2$-adrenergic receptors, and Group II/III mGluRs) inhibit adenylyl cyclase, open potassium channels, and block calcium channels, generating hyperpolarizing inhibitory postsynaptic potentials and suppressing neurotransmitter release.